Now showing items 1-1 of 1

    • Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. 

      Mateo, J; Porta, N; Bianchini, D; McGovern, U; Elliott, T; Jones, R; Syndikus, I; Ralph, C; Jain, S; Varughese, M; Parikh, O; Crabb, S; Robinson, A; McLaren, D; Birtle, A; Tanguay, J; Miranda, S; Figueiredo, I; Seed, G; Bertan, C; Flohr, P; Ebbs, B; Rescigno, P; Fowler, G; Ferreira, A; Riisnaes, R; Pereira, R; Curcean, A; Chandler, R; Clarke, M; Gurel, B; Crespo, M; Nava Rodrigues, D; Sandhu, S; Espinasse, A; Chatfield, P; Tunariu, N; Yuan, W; Hall, E; Carreira, S; de Bono, JS (2020-01)
      <h4>Background</h4>Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations ...